logoAiPathly

Umoja Biopharma

U

Overview

Umoja Biopharma is a pioneering biotechnology company focused on developing innovative immunotherapies, particularly in the field of cell and gene therapies. The company's mission is to unlock the potential of CAR T cell therapies, making them more accessible, scalable, and effective for patients with solid tumor and blood cancers. Umoja's integrated scientific platforms include:

  1. VivoVec: A proprietary, third-generation lentiviral vector technology for in vivo gene delivery, enabling the body to produce its own cancer-fighting CAR T cells.
  2. RACR (Rapamycin-Activated Cytokine Receptor): A system using rapamycin to support the survival and expansion of CAR T cells generated in vivo, eliminating the need for lymphodepletion via chemotherapy.
  3. iCIL (RACR-induced cytotoxic lymphocytes): A platform generating synthetic cancer-fighting cells from induced pluripotent stem cells (iPSCs) at a large scale.
  4. TumorTag: A small molecule that 'tags' cancer and its stromal cells, allowing precise targeting by CAR T cells. Umoja's manufacturing capabilities are centered around The CLIMB (Colorado Laboratory & Innovative Manufacturing Building), a state-of-the-art facility in Louisville, Colorado. This facility supports lentiviral vector development and manufacturing through Phase 2 clinical studies. The company is led by a team of experienced professionals, including co-founders Andrew Scharenberg, MD (CEO) and Ryan Crisman, PhD (CTO). Umoja's approach aims to overcome limitations of current ex vivo cellular immunotherapies by developing 'off-the-shelf' cell therapies that are scalable, cost-effective, and widely accessible.

Leadership Team

Umoja Biopharma's leadership team comprises experienced professionals from the biotechnology and pharmaceutical industries: Executive Leadership:

  • Andrew Scharenberg, MD: Co-founder and CEO
  • Ryan Crisman, PhD: Co-founder and CTO
  • David Fontana, PhD: COO and CBO
  • Britton Russell: CFO
  • Chris Moore, JD: Chief Legal Officer Senior Vice Presidents:
  • Ryan Larson, PhD: SVP and Head of Research
  • Sally M. Dyer: SVP and General Manager of Colorado Operations
  • Jacob Garcia, MD: SVP of Clinical Operations & Development
  • Helen Kim: SVP of Regulatory Affairs
  • Jennifer Lester, MA: SVP of IT & Informatics
  • Bruce Kerwin, PhD: SVP of Process and Product Development Vice Presidents:
  • Chris Lewis: VP of Quality
  • Geoff Quinn: VP of Corporate Operations
  • Mae-Lee Pang: VP of Human Resources
  • Mike Fitzpatrick: VP of Business Development and Operations Board of Directors:
  • Scott Myers: Chairman
  • Andrew Scharenberg, MD: CEO
  • Luke Evnin, PhD: MPM Capital representative
  • John Hamer, PhD: DCVC Bio representative
  • Anna French, PhD: Qiming Venture Partners USA representative Advisory Board:
  • Michael Jensen, MD: Co-founder and Co-chair of Scientific Advisory Board
  • Hans-Peter Kiem, MD, PhD: Fred Hutch Endowed Chair for Cell and Gene Therapy
  • Rimas Orentas, PhD: Ben Towne Center for Childhood Cancer
  • Igor I Slukvin, MD, PhD: University of Wisconsin, Madison This diverse team brings extensive experience in immunotherapy, cell and gene therapy, drug development, and business operations to drive Umoja Biopharma's mission forward.

History

Umoja Biopharma, a Seattle-based biotechnology company, was founded in 2019 by a team of experienced professionals:

  • Dr. Andrew Scharenberg: Co-founder and CEO
  • Dr. Michael Jensen: Vice President of Seattle Children's Therapeutics
  • Dr. Philip Low: Professor at Purdue University
  • Ryan Crisman: Co-founder and CTO The company's technology is based on pioneering work from Seattle Children's Research Institute and Purdue University, focusing on in vivo CAR T-cell immunotherapy. Key milestones:
  1. 2020: Raised $53 million in Series A funding
  2. 2021: Secured an additional $210 million in funding
  3. January 2025: Announced a $100 million Series C round
  4. November 2024: Appointed Scott Myers as Chairman of the Board Umoja has established a state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado, addressing scalability and manufacturing challenges. The company's pipeline includes several preclinical programs and one program, UB-TT170, which has entered Phase 1 trials. Umoja aims to initiate clinical trials in multiple geographies and has recently initiated its first US IND. Umoja Biopharma's mission is to transform the delivery of CAR-T cell therapies, making them more accessible and effective for a broader range of patients with cancer.

Products & Solutions

Umoja Biopharma, a clinical-stage biotechnology company, is at the forefront of developing innovative immunotherapies for oncology and autoimmunity. Their key products and solutions include:

VivoVec™ In Vivo Gene Delivery Technology

VivoVec™ is Umoja's flagship platform that enables direct in vivo delivery of genetic material to generate CAR-T cells within the patient's body. This groundbreaking approach eliminates the need for external cell modification, addressing time lag and manufacturing challenges associated with traditional ex vivo CAR-T cell therapies.

RACR/CAR In Vivo Cell Expansion/Control Platform

This platform utilizes the Rapamycin Activated Cytokine Receptor (RACR) to control and expand immune cells in vivo. By inducing cell expansion and persistence through rapamycin infusion, the RACR system enhances immunotherapy efficacy.

TumorTag Targeting Platform

TumorTag improves tumor cell targeting by labeling multiple targets within the tumor environment with bispecific small molecule adapters (TumorTags). These TumorTags are recognized by universal TagCAR expressed on engineered immune cells, enhancing treatment precision and efficacy.

Engineered Induced Pluripotent Stem Cells (iPSCs)

Umoja is developing an 'off-the-shelf' immunotherapy platform using engineered iPSCs designed to differentiate into lymphocytes such as T cells and natural killer (NK) cells. This approach aims to overcome challenges associated with patient-derived cells, including limited expansion capacity, manufacturing complexity, and high cost.

Strategic Collaborations

  1. Lupagen: Umoja is collaborating with Lupagen to evaluate the use of Lupagen's extracorporeal in vivo delivery system, Side CAR-T™, to enhance the delivery of Umoja's VivoVec particles.
  2. AbbVie: Umoja has entered into a strategic collaboration with AbbVie to develop multiple in-situ generated CAR-T cell therapy candidates using Umoja's VivoVec™ platform. This includes developing up to four additional CAR-T cell therapy candidates for targets selected by AbbVie. These innovative technologies and strategic partnerships underscore Umoja Biopharma's commitment to broadening access to advanced immunotherapies, improving their effectiveness, and enhancing the patient experience.

Core Technology

Umoja Biopharma's core technology revolves around several innovative platforms designed to enhance and expand the reach of CAR T cell therapies, particularly in oncology and autoimmunity:

VivoVec™ Technology

The flagship VivoVec™ platform is an in vivo gene delivery system that enables direct generation of CAR T cells within the patient's body. This technology uses lentiviral vectors to deliver genetic material to the patient's T cells, empowering the body's immune system to fight disease without the need for external cell modification.

RACR-induced Cytotoxic Lymphocytes (iCIL)

Umoja is developing RACR-induced cytotoxic lymphocytes (iCIL) using the RACR (rapamycin activated cytokine receptor) technology. This platform generates synthetic cancer-fighting cells from induced pluripotent stem cells, which can be administered to patients to augment their anti-tumor immune function and work in conjunction with VivoVec-generated CAR T cells.

RACR/CAR™ and TumorTag™ Platforms

These platforms support the survival and targeting of tumor-fighting T cells:

  1. RACR/CAR™: This payload architecture stimulates the body to grow tumor-fighting T cells.
  2. TumorTag™: This platform directs the cells to attack the tumor, enhancing therapeutic effect while minimizing adverse events.

Manufacturing and Development

Umoja Biopharma operates a state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. This facility is crucial for the production and development of the lentiviral vectors used in the VivoVec™ technology. These integrated platforms work synergistically to overcome the limitations of current ex vivo cellular immunotherapies. By increasing effectiveness, reducing barriers, and expanding access to CAR T cell therapies, Umoja Biopharma aims to revolutionize the field of immunotherapy and improve patient outcomes.

Industry Peers

Umoja Biopharma operates in the biopharmaceutical industry, focusing on immunotherapy and CAR-T cell therapies. The company's key competitors and industry peers include:

Major Competitors

  1. Genentech: Known for innovative cancer therapies and a significant player in immunotherapy.
  2. Bristol-Myers Squibb: Recognized for immunotherapy drugs and substantial investments in research and development.
  3. Merck & Co.: Made significant advancements in immunotherapy, particularly with checkpoint inhibitors.
  4. Gilead Sciences: Although primarily known for antiviral drugs, Gilead has ventured into immunotherapy for cancer and other diseases.
  5. Novartis: A multinational pharmaceutical company with a strong presence in oncology and developing promising immunotherapy drugs.

Other Industry Peers

  • Novavax: Known for vaccine development and involved in various biotechnological research areas.
  • Regeneron: Develops treatments for various diseases, including cancer and autoimmune disorders.
  • Sanofi: A global pharmaceutical company with a diverse portfolio that includes immunotherapies.
  • Johnson & Johnson: Major pharmaceutical company with significant investments in oncology and immunotherapy.
  • Moderna: Known for mRNA-based therapies and exploring immunotherapy options.
  • Pfizer: Global pharmaceutical giant with a broad range of therapeutic areas, including oncology and immunology.
  • AstraZeneca: Major pharmaceutical company with a strong focus on oncology and immunotherapy.

Strategic Partners

Umoja Biopharma has established strategic collaborations to enhance its position in the industry. A notable partnership is with AbbVie, focusing on developing in-situ generated CAR-T cell therapy candidates using Umoja's VivoVec™ platform. This competitive landscape highlights the dynamic nature of the immunotherapy field, with various companies pursuing innovative approaches to treat cancer and autoimmune disorders. Umoja Biopharma's unique in vivo CAR-T cell generation technology positions it as a potential disruptor in this rapidly evolving industry.

More Companies

Z

Zeekr

Zeekr is a premium electric vehicle (EV) brand founded in March 2021 by the Geely Group, a leading global mobility company. Key aspects of Zeekr include: ### Ownership and Brand Philosophy - Owned by Geely Automobile Holdings, operating as Zeekr Intelligent Technology Holding Limited - Name derived from 'Generation Z' and 'geek', reflecting focus on technology and innovation - Aims to be a user-driven tech company centered on experiences and innovation ### Product Line - Zeekr 001: Full-size shooting brake, first model launched in April 2021 - Other models: Zeekr 007 (mid-size sedan), Zeekr 009 (full-size MPV), Zeekr X (subcompact SUV), Zeekr 7X (mid-size SUV), Zeekr Mix (compact MPV) ### Technology and Innovation - Vehicles built on the Sustainable Experience Architecture (SEA) platform - Features include 800V high voltage charging and CATL Qilin long-range batteries - Collaborations with Waymo for autonomous ride-hailing vehicles and Mobileye for L4 autonomous capabilities ### Manufacturing and Global Presence - Manufacturing capacity of up to 300,000 vehicles per year in China - R&D facilities in Ningbo, Hangzhou, and Shanghai - Global design center in Gothenburg, Sweden, and European HQ in Amsterdam - Expanded sales to over 330 cities in China and launched in Europe in 2023 ### Financial Growth - Raised $500 million in 2021 and $750 million in 2023, valuing the company at $13 billion - Filed for IPO on NYSE in May 2024, raising approximately $441 million Zeekr positions itself as a premium EV brand focusing on technology, innovation, and user-centric design, aiming to compete globally in the electric vehicle market.

A

Automattic

Automattic is a globally distributed company that has significantly impacted the web publishing and commerce landscape since its founding in 2005. Here are key aspects of the company: ### Founding and Headquarters Founded by Matt Mullenweg, co-founder of WordPress, Automattic is headquartered in San Francisco, California, USA. ### Products and Services Automattic offers a wide range of popular web services and tools, including: - WordPress.com - WooCommerce - Jetpack - WordPress VIP - Simplenote - Longreads - Tumblr - Day One - Pocket Casts - Newspack - Beeper ### Global Presence and Workforce As a distributed company, Automattic employs approximately 2,000 people across 96 countries, speaking over 120 different languages. ### Mission and Values Automattic is committed to democratizing publishing and commerce, aiming to enable anyone to share their story or sell their product regardless of background or location. The company strongly supports Open Source, with most of its work available under the GPL (General Public License). ### Culture and Work Environment Operating as a remote-only, asynchronous organization, Automattic emphasizes clear communication, respect for boundaries, and inclusivity. The company supports equity measures for employees with disabilities and promotes a culture that respects diverse backgrounds and experiences. ### Contribution to Open Source Automattic dedicates 5% of its company time to the WordPress core project, an initiative known as "Five for the Future," encouraging businesses and individuals to contribute to WordPress development. ### Recognition Automattic is recognized as a Most Loved Company and is committed to being Disability Confident. In summary, Automattic is a forward-thinking company that values diversity, inclusion, and the democratization of web publishing and commerce while significantly contributing to the Open Source community.

E

Exabeam

Exabeam is a global cybersecurity leader specializing in AI-driven security operations. The company offers a comprehensive suite of products and services designed to enhance threat detection, investigation, and response (TDIR). Key aspects of Exabeam include: ### AI-Driven Security Operations Exabeam integrates AI and machine learning into its security operations platform, delivering advanced behavioral analytics on top of traditional security information and event management (SIEM) capabilities. This approach helps detect anomalies and suspicious activities by learning normal behavior patterns within an organization. ### Exabeam Security Operations Platform The cloud-native and scalable platform provides advanced capabilities for log management, SIEM, and TDIR. Key features include: - Over 200 prepackaged correlation rules and a rule builder - Collectors that gather data from various sources - Log Stream for rapid log processing with over 10,000 pre-built parsers - Outcomes Navigator for actionable security coverage recommendations - Automation Management with no-code playbooks - Threat Center, a unified workbench for threat detection and response ### Advanced Analytics and Automation Exabeam automates every step in the TDIR workflow, from data collection to the final stages of investigation. This automation enables security analysts of all skill levels to conduct comprehensive investigations efficiently. The platform uses generative AI to provide event context and accelerate investigations. ### Integrated Threat Intelligence The solutions include integrated threat intelligence, improving the fidelity of detections by adding context to correlation rules. This integration helps in more accurate and efficient threat management. ### Scalability and Flexibility The platform is designed to handle large volumes of data, offering limitless scale to ingest, parse, store, search, and report on petabytes of data. It also provides flexible deployment options to suit various organizational needs. ### User-Friendly Interface Exabeam's interface is designed to be user-friendly, allowing both new and experienced analysts to easily navigate and manage the platform. Features like customizable dashboards and fast, scalable searches across hot and cold data enhance usability and efficiency. Overall, Exabeam's solutions aim to break the cycle of constant recovery by providing innovative, AI-driven security operations that empower organizations to detect, defend against, and defeat cyber threats effectively.

L

LambdaTest